Investor service announcement no. 6/2011



To: NASDAQ OMX Copenhagen
Hørsholm, Denmark, September 8, 2011






Veloxis Pharmaceuticals A/S to Present at Rodman & Renshaw Annual
Global Investment Conference



Veloxis Pharmaceuticals A/S (OMX: VELO), formerly LifeCycle Pharma A/S, today
announced that John Weinberg, M.D., senior vice president, commercial
operations & investor relations of Veloxis, will present at the Rodman &
Renshaw Annual Global Investment Conference at 9:35 a.m. EDT, Monday, Sept. 12,
at The Waldorf=Astoria in New York. Dr. Weinberg will provide an overview of
the company and discuss top-line Phase 3 results of LCP-Tacro™, Veloxis'
candidate to prevent organ transplant rejection.



For more information, please contact:



John Weinberg, M.D.
SVP, Commercial Operations & Investor Relations
Tlf: +1 908 304 3389
Email: [email protected]


Veloxis Pharmaceuticals A/S (VELO)


Based in Hørsholm, Denmark, with an office in New Jersey, Veloxis
Pharmaceuticals A/S, or Veloxis, is a specialty pharmaceutical company.
Clinical development is the core of Veloxis' efforts to develop a product
portfolio which includes the Company's lead product candidate, LCP‐Tacro™, for
immunosuppression, specifically organ transplantation, and products to combat
certain cardiovascular diseases. Veloxis adapts new technologies on a fast
commercial timetable. Veloxis' unique, patented delivery technology, MeltDose®,
can improve absorption and bioavailability ‐ at low‐scale up costs ‐ not only
for a broad spectrum of drugs already on the market but also for new chemical
entities. Veloxis has a lipid lowering product, Fenoglide®, currently on the
U.S. market and a diversified near and medium term pipeline with three clinical
stage product candidates and a number of projects in preclinical development.
Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX:
VELO.


For further information, please visit www.veloxis.com.

080911 Veloxis Pharmaceuticals to Present at Rodman Renshaw Annual Global Investment Conference.pdf